CDMS, the process generally includes:

1. Define user roles within the role matrix
2. Assign role templates to study-level user profiles
3. Enable blinded vs. unblinded flags for relevant roles
4. Apply site-level overrides for country-specific permissions
5. Lock user profiles post-activation and review monthly

A role like “Query Manager” may only access the query module and CRF pages marked for review, while a “Clinical Coder” may access AE verbatim terms only.

Configuring Access Permissions in eTMF Systems

eTMF platforms such as Veeva Vault eTMF or Wingspan have advanced permissioning tools. Best practices include:

• Document Class–Based Permissions: Grant or restrict access based on document type (e.g., ICF, Protocol, Budget)
• Workflow-Linked Roles: Assign permissions based on workflow status (e.g., Draft, QC, Final, Approved)
• External Share Links: Restrict link access duration and recipient domains for external auditors
• Folder-Level Permissions: Apply top-down access for Trial, Country, and Site folders

For instance, a CRA can access Site Close-Out Visit Reports in PDF, but not scanned contracts or SAE listings.

Validation of Permission Controls in GxP Systems

Clinical IT teams must validate all permission rules using GAMP 5 principles. Validation includes:

• OQ Tests: Confirm that users with assigned roles can and cannot perform actions as expected
• PQ Scenarios: Simulate a real-world audit access request and check access expiration
• Audit Log Review: Verify traceability of role changes and permission overrides

For validated test scripts, explore PharmaValidation.in.

Regulatory Examples: Inspection Observations and Best Practices

During a 2022 MHRA inspection, a UK-based sponsor received a major finding:

“EDC platform permitted CRAs to export unblinded data across all sites, violating randomization masking policies.”

In response, the sponsor implemented blinded role segregation and a change control SOP for any role edits. Regulatory authorities often review:

• User provisioning logs
• Inactive account lists
• Permission change histories

Access records should be archived within the eTMF for the duration of the trial retention period.

Using Blockchain to Audit Permission Changes

Blockchain audit trails now enable tamper-evident tracking of permission changes. Benefits include:

• Immutable timestamp of access revocations
• Smart contract enforcement of role expiration
• Geo-tagged access logs for decentralized trial compliance

See examples of blockchain-audited access control in clinical settings at PharmaGMP.in.

Documenting Permissions in SOPs and TMF

Every EDC/eTMF role definition and change must be documented. Common SOP elements:

• Role Permission Matrix
• User Onboarding/Offboarding Steps
• Periodic Role Review Frequency (e.g., quarterly)
• Backup Role Assignment for Delegation

These SOPs must be version controlled and filed in the eTMF under the “System Configuration” zone.

Conclusion: Securing Trial Data Through Proper Permissions

Setting permissions in EDC and eTMF platforms is more than IT configuration—it’s a core GxP compliance activity. Improper permissions can expose sensitive patient data, lead to blinded data compromise, and result in costly inspection outcomes.

Sponsors and CROs must implement SOP-driven, validated, and regularly reviewed permission structures. For global trials, configurations should account for cross-border rules and regional expectations.

Refer to FDA and EMA guidelines, and explore access SOP templates at PharmaSOP.in to strengthen your compliance posture.